http://chineseinput.net/에서 pinyin(병음)방식으로 중국어를 변환할 수 있습니다.
변환된 중국어를 복사하여 사용하시면 됩니다.
- 中文 을 입력하시려면 zhongwen을 입력하시고 space를누르시면됩니다.
- 北京 을 입력하시려면 beijing을 입력하시고 space를 누르시면 됩니다.
RISS 인기검색어
- 검색키워드
- 저자 : Yee Hyuk Kim (검색결과 40 건)
- 무료
- 기관 내 무료
- 유료
-
Yee-Hyuk Kim,Sung-Yong Choi,Young-Ho Lee 대한청각학회 2011 Journal of Audiology & Otology Vol.15 No.3
Background and Objectives: Corticosteroids have been used for therapeutic management of sudden sensorineural hearing loss (SSNHL). Because of the complications associated with systemic steroid therapy and low levels of steroid in the inner ear after systemic administration, intratympanic steroid injection (ITSI) is currently used. The purpose of this study was to compare the efficacy of systemic steroid therapy with systemic combined high frequency ITSI therapy. Subjects and Methods: Forty-six SSNHL patients were divided into the only systemic dexamethasone therapy group (systemic steroid IV group, 27 patients) and the systemic with frequent intratympanic dexamethasone injection group (combined ITSI group, 19 patients). In the systemic steroid IV group, dexamethasone was administered intravenously for 5 days followed by oral tapered doses for 10 days. In the combined ITSI group, intratympanic dexamethasone was administered 5 times per day for 5 consecutive days in addition to intravenous administration of dexamethasone. Hearing was assessed both before therapy and at 15 days, 4 weeks, and 8 weeks after the initiation of therapy. Results: The recovery rate and hearing gain were 74% (20 out of 27 patients) and 33 dB mean improvement in the systemic steroid IV group and 73.6% (14 out of 19 patients) and 41.5 dB mean improvement in the combined ITSI group. There was no statistically significant difference in hearing gain and the recovery rate between the two groups. Conclusions: The therapeutic effect of a combination of highly frequently administered intratympanic dexamethasone and systemic steroid therapy was not superior to only systemic steroid injection therapy. Introduction Sudden sensorineural hearing loss (SSNHL) is considered as an otologic emergency. Evaluation of treatments has been hampered by the low incidence of SSNHL, unknown natural history and the tendency for spontaneous hearing recovery (30-60%).1) The spontaneous hearing improvement in untreated patients usually occurs within 2 weeks after the onset of hearing loss.2) After 2 weeks of the onset of hearing loss, it becomes difficult to expect a spontaneous recovery. The current treatment of choice for hearing loss is either oral or intravenous administration of systemic steroids. However, the effectiveness of steroids in the treatment of idiopathic SSNHL still remains unproven.3) Treatment modalities that have been tried include the use of combination of corticosteroids, vasodilators, anti-viral agents, diuretics, hyperbaric oxygen, stellate ganglion block and low-salt diet.3)Intratympanic steroids are being increasingly used as a therapeutic option for SSNHL because of the advantages of intratympanic steroid injection like, nil occurrences of systemic effects of steroid treatment and increase in the amount of steroid entering the inner ear when compared to systemic injections. In particular, intratympanic steroids have been shown to be effective as a salvage treatment for SSNHL patients, who had no relief from the initial systemic treatment.4,5,6)Endolymphatic dexamethasone level shows the highest concentration within 1-2 hours after intratympanic dexamethasone injection and then there is a sharp reduction.7) We consider that it is useful to maintain a high concentration of dexamethasone in the endolymph by highly frequent intratympanic steroid injection (ITSI) therapy. The purpose of this study was to compare the efficacy of systemic steroid therapy with systemic combined high frequency ITSI therapy. Subjects and Methods Study design and patients The study included hospitalized patients that were diagnosed with SSNHL between August 2008 and January 2010. The diagnostic criteria for SSNHL were the acute onset of hearing loss of 30 dB or more over at least three contiguous audiometric frequencies, which may have occurred within 3 days. The treatments were initiated within 7 days after the occurrence of SSNHL. A total of 46 SSNHL patients were divided into 2 different treatment groups on a random basis. One group (systemic steroid IV group, 27 patients) was treated with systemic dexamethasone therapy and the other group (combined ITSI group, 19 patients) was treated with systemic dexamethasone and frequent intratympanic dexamethasone injection. In the systemic steroid IV group, dexamethasone was administered intravenously for 5 days followed by tapered doses orally for 10 days. In the combined ITSI group, intratympanic dexamethasone was administered 5 times per day for 5 consecutive days (from 9 AM to 9 PM at intervals of 3 hours) in addition to intravenous dexamethasone administration. Informed consent was obtained from every individual study subject. All the patients underwent medical history, physical and laboratory examinations and brain magnetic resonance image MRI scanning. Subjects with medical or central nervous system conditions, including syphilis, chronic renal disease, cardiovascular disease and retrocochlear lesion were excluded from the study. Subjects with true whirling type vertigo, family history of hearing loss, history of fluctuating hearing loss, head trauma and otologic surgery were also excluded from the investigation. Treatment protocol All the patients in both the groups were hospitalized for 5 days and treated with intravenous dexamethasone (10 mg) (dexamethasone®, Jeil Pharm, Seoul, Korea) for 5 days and subsequently with oral methylprednisolone (Methylon®, 4 mg/1T, KunWha Pharm, Seoul, Korea) for 10 days in tapered doses (48 mg, 40 mg, 32 mg, 24 mg, each for 2 days decreasing by 8 mg each 2 day, and 12 mg at the last 2 days), after which the patients were discharged from the hosp...
-
Yee Zee Bae,Jae Hyuk Jung,Chang Hoon Moon,Seong Hyun Kim,Hyuk Chan Kwon,Jae Seok Kim,Hyo Jin Kim 대한암학회 2002 Cancer Research and Treatment Vol.34 No.3
Purpose: There are few therapeutic options in patientswith colorectal cancer that have progressed or recurredfollowing 5-fluorouracil (5-FU) based therapy. We evaluatedthe efficacy and toxicity of oxaliplatin, 5-FU, leucovorin(Mayo clinic regimen) in 5-FU pretreated advancedcolorectal cancer patients.Materials and Methods: Twenty-eight patients wereenrolled in this study between January 1999 and May2001. Patients were treated with oxaliplatin 150 mg/m2 onday 1 as a 2-hr infusion and 5-FU 425 mg/m2, leucovorin20 mg/m2, bolus for 5 days. Treatment courses wererepeated in 4-week intervals.Results: The objective response rate was 25% for 28assessable patients, all cases registered a partial response.Eleven patients (39%) demonstrated stable disease,and ten (36%) progressed. The median responseduration was 5.5 months, and the median time to progressionwas 6.3 months. The median overall survivaltime was 13.5 months from the start of the chemotherapy.From the 120 cycles analyzed, grade 3,4 hematologictoxicities included neutropenia: 1.6%, and thrombocytopenia:1.6%. The frequent grade 3.4 non-hematologicadverse reactions were nausea/vomiting (25.0%), diarrhea(14.3%), stomititis (3.6%), and neuropathy (3.6%). Therewere no treatment-related deaths.Conclusion: This phase II study had relatively highertoxicity than previous studies, and did not show anincreased significant response rate. These high levels oftoxicity suggest that the study treatment combination ofoxaliplatin with a full dose Mayo clinic regimen arm is nofeasible. Therefore, this regimen will be discontinued anda safer regimen will be adopted. (Cancer Res Treat. 2002;34:218-222)
-
Je Hyuk Chung,Yee Zee Bae,Sung Hyun Kim,Chang Hoon Moon,Jun Young Chung,Hyuk Chan Kwon,Jae Seok Kim,Hyo Jin Kim 대한암학회 2002 Cancer Research and Treatment Vol.34 No.5
Purpose: There is no effective treatment for patientswith advanced gastric cancer having failed to respond tofirst line chemotherapy. The aim of this study was toevaluate the therapeutic activity, and safety, of a FEPregimen in patients with a recurrence of, or metastatic,gastric cancer that had been unresponsive to primarychemotherapy.Materials and Methods: Recurred or metastatic gastriccancer patients that did not respond to a 5-fluorouracilbased regimen were entered into this trial. The patientswere treated with FEP (5-FU, etoposide and cisplatin) assalvage chemotherapy. The treatment regimen was 5-FU(900 mg/m2/day) by continuous infusion for 3 days, etoposide(90 mg/m2/day) on days 1, 2 and 3, and cisplatin(60 mg/m2/day) on day 2. This treatment was repeatedevery 3 weeks.Results: Between December 1997 and October 2001, 28patients were enrolled to the study. The response rate was32.1% (95% CI 15.5~57.8%). The median times to progressionand survival duration were 23~33 weeks, respectively.Among a total of 187 cycles of chemotherapy, the grade3 and 4 hematological toxicities were leukopenia (6.4%),thrombocytopenia (1.6%), and grade 3 non-hematologicalside effects of nausea/vomiting (17.9%).Conclusion: FEP combination chemotherapy seems tobe an effective treatment regimen for gastric cancer assalvage chemotherapy. To confirm these results, largescale of clinical trials will be required. (Cancer Res Treat. 2002;34:382-387)
-
Junsoo Kim,Soo-Jung Kim,Jung Yoon Kwon,Wonchul Choi,Hyuk Jin Kim,Taekwang Kim,Sol Yee Im,Jaewoo Lee,이승민,장문규,Seung Eon Moon 한국물리학회 2016 THE JOURNAL OF THE KOREAN PHYSICAL SOCIETY Vol.68 No.12
To study the electric and the thermoelectric properties of silicon thin films (SiTFs), we fabricated devices having SiTFs by using conventional complementary metal-oxide-semiconductor (CMOS)- compatible processes for mass production and extendibility. The conductivities and the Seebeck coefficients of SiTFs for dose concentrations of 5 × 1014 cm−2, 1 × 1015 cm−2 and 5 × 1015 cm−2 and for temperatures in the range of 310 to 430 K were measured by using homemade setup. The measured power factors of the SiTFs showed a slight increasing tendency with increasing measurement temperature and were maximum at a dose concentration of 1 × 1015 cm−2 for both n- and p-type films at 330 K.
-
-
-
( Se Hyun Kim ),( Jee Hyun Kim ),( Tae Yong Kim ),( In Sil Choi ),( Yee Soo Chae ),( Sun Kyung Baek ),( Seok Yun Kang ),( In Hae Park ),( Yoon Ji Choi ),( Soo Hyeon Lee ),( Joo Hyuk Sohn ),( Yeon Hee 대한내과학회 2014 대한내과학회 추계학술대회 Vol.2014 No.1
Background: The ratio of involved to retrieved lymph nodes (LNR) is suggested as a prognostic factor in operable breast cancer. However, there are confi icting results regarding its clinical signifi cance after neoadjuvant chemotherapy. We investigated the prognostic value of LNR with a thorough evaluation of potential prognostic factors in a large cohort constructed from Health Insurance Review and Assessment Service database of Korea. Methods: This retrospective analysis is based on the data of 814 patients with clinical stage II/III breast cancer treated with four cycles of adriamycin/cyclophosphamide followed by four cycles of docetaxel before surgery. We evaluated the clinical signifi - cance of the LNR (3 categories: Low, 0-0.20 vs. Intermediate, 0.21-0.65 vs. High, 0.66 -1.00) using Kaplan-Meier method, log-rank test, and Cox proportional hazard regression model. Results: A total of 799 patients underwent breast surgery (Median age 45, range 16- 74; Mastectomy 369, Lumpectomy 380, and Others 50). Axillary lymph node dissection was performed in 704 (88.1%) patients. Pathologic complete response (pCR) was achieved in 129 (16.1%) of 799 patients (HR+/HER2-, 34/373 [9.1%]; HER2+, 45/210 [21.4%]; TNBC 50/216 [23.1%]). The mean numbers of involved LN and retrieved LN were 2.70 (range 0-42) and 13.98 (range 1-64), respectively. The mean LNR was 0.17 (Low, 574 [71.8%]; Intermediate, 170 [21.3%]; High, 55 [6.9%]). In univariate analysis, LNR was signifi cantly associated with worse relapse-free survival (3-yr RFS rate 84.8% in low vs. 66.2% in intermediate vs. 54.3% in high; P <0.0001, log-rank test). In multivariate analysis, LNR was not signifi cantly associated with recurrence after adjustment of other clinical factors (Age, histologic grade, intrinsic subtype, ypT-stage, ypN-stage, lymphatic or vascular invasion, and pCR). Conclusions: LNR is not superior to ypN-stage in predicting clinical outcome of breast cancer after neoadjuvant chemotherapy.
-
김경태 ( Kyoung Tae Kim ),백정환 ( Jeung Hoan Paik ),이창재 ( Chang Jae Lee ),김진호 ( Jin Ho Kim ),배이지 ( Yee Zee Bae ),서봉근 ( Bong Gun Seo ),권혁찬 ( Hyuk Chan Kwon ),오성용 ( Sung Yong Oh ),김성현 ( Sung Hyun Kim ),김재석 ( 대한내과학회 2005 대한내과학회지 Vol.69 No.3
목적: 다발성골수종은 단일 클론에서 유래하는 B 림프구의 악성종양으로 형질세포의 악성증식을 특징으로 하는 질환이다. 다발성 골수종은 임상 양상이 매우 다양하게 나타나며 생존율은 수개월에서 10년 이상으로 다양하다. 이 연구의 목적은 다발성골수종에서 특정한 세포유전학적 염색체 결함이 예후인자로서 가치가 있는지 알아보고자 하였다. 방법: 1995년 4월부터 2004년 8월까지 다발성골수종으로 진단 받은 환자 40예를 대상으로 하였다. 세포유전학적 검사는 세포중기 핵형분석을 하여 염색체 검사를 시행하였다. 정상염색체를 보인 군(A군)과 13번 염색체 결손 또는 부분 결손이나 저두배수체를 보이는 군(B군), 그리고 그 외의 염색체 이상을 보이는 군(C군)으로 분류하였다. 결과: 관찰기간의 중앙값은 13.1개월이었다(범위 1.5~92.1개월). 항암화학요법에 대한 총 반응율은 58.8%였고, A군, B군, C군 간의 치료에 대한 반응율은 각각 56.3%, 33.3%, 75%였다(p=0.229). 생존기간에 영향을 미치는 예후인자로는 임상적 병기, 활동도, 혈청 크레아티닌 수치, 성별 그리고 염색체 이상 여부 등이었다. A군, B군, C군 사이에 중앙생존기간이 유의하게 차이가 있었으며(각각 34.9개월, 8.5개월, 19.8개월, p=0.0125), 염색체 이상 중 13번 염색체 결손 또는 부분 결손과 염색체 저두배수체성이 다발성골수종에서 생존기간에 불리하게 작용하였다. 결론: 다발성 골수종에서 진단시 염색체 이상은 임상적 예후에 중요한 인자로 작용한다. Background: Multiple myeloma is a clonal B-cell malignancy manifested by the accumulation of terminally differentiated plasma cells. The disease is characterized by clinical heterogeneity, with survival ranging from a few months to more than 10 years. The purpose of this study is to evaluate the prognostic value of specific chromosomal abnormality in multiple myeloma. Methods: We analyzed the clinical records of 40 patients who were diagnosed as multiple myeloma, between April, 1995 and August, 2004. Cytogenetic analysis was conducted by metaphase karyotype analysis. Patients were grouped into normal cytogenetic group (arm A), complete or partial deletion of chromosome 13 and hypodiploidy group (arm B) and other cytogenetic abnormality group (arm C). Results: Median follow up duration was 13.1 months (range 1.5-92.1). Overall response rate to chemotherapy was 58.8% and response rate among arm A, B and C were 56.3%, 33.3% and 75%, respectively (p=0.229). The prognostic factors affecting survival were clinical stage, performance status, serum creatinine level, sex and chromosomal abnormality. The median overall survival was significantly different among arm A, B and C (34.9 months, 8.5 months and 19.8 months, respectively, p=0.0125). Conclusion: chromosomal abnormality, especially, complete or partial deletion of chromosome 13 and hypodiploidy at initial diagnosis is significantly associated with survival duration. (Korean J Med 69:303-311, 2005)
-
-
Park, Yeon Hee,Im, Seock-Ah,Kim, Sung-Bae,Sohn, Joo Hyuk,Lee, Keun Seok,Chae, Yee Soo,Lee, Ki Hyeong,Kim, Jee Hyun,Im, Young-Hyuck,Kim, Ji-Yeon,Kim, Tae-Yong,Lee, Kyung-Hun,Ahn, Jin-Hee,Kim, Gun Min,P Elsevier 2017 European journal of cancer Vol.86 No.-
<P><B>Abstract</B></P> <P><B>Background</B></P> <P>Paclitaxel plus gemcitabine (PG) combination chemotherapy is a preferred chemotherapeutic regimen for patients with metastatic breast cancer (MBC). Eribulin mesylate is a halichondrin non-taxane inhibitor of microtubule dynamics. A recent pooled analysis with eribulin showed improved overall survival (OS) in various MBC patient subgroups pretreated with anthracycline and taxane. Furthermore, eribulin may have less neurotoxicity than paclitaxel.</P> <P><B>Patients and methods</B></P> <P>This study was a prospective randomised phase II, open-label, two-arm, multicentre study comparing eribulin plus gemcitabine (EG) with PG chemotherapy as a first-line treatment for patients with human epidermal growth factor receptor 2-negative MBC. We hypothesised that EG chemotherapy would not be inferior to PG chemotherapy. The primary end-point was progression-free survival (PFS), which was estimated to be 70% at 6 months for each arm. The secondary end-points were as follows: OS, neuropathic scale, toxicity and clinical benefit rate.</P> <P><B>Results</B></P> <P>A total of 118 patients (median age: 50, 24–66) were enrolled between March 2015 and March 2016 and were randomly assigned to PG (<I>n</I> = <I>59</I>) or EG (<I>n</I> = <I>59</I>) chemotherapy. The mean number of metastatic sites was 3 (range 1–8). The 6-month PFS rates for both arms were 72% for EG and 73% for PG (<I>P</I> = <I>0.457</I>). There was no significant difference in OS between the two groups (not reached versus 21.2 months, <I>P</I> = <I>0.2234</I>). The median number of chemotherapy cycles for both groups was 10 for EG and 8 for PG (range 2–32). Clinical benefit rates were 44% for EG and 49% for PG. Major toxicities were neutropenia and neurotoxicity. Grade II or above neurotoxicity was more common with PG than with EG (13.6% for EG versus 45.8% for PG, <I>P</I> < <I>0.0001</I>).</P> <P><B>Conclusion</B></P> <P>EG chemotherapy had similar clinical benefits to PG chemotherapy in terms of PFS but less neurotoxicity.</P> <P><B>Trial registration</B></P> <P>KCSG BR13-11; ClinicalTrials.gov, NCT02263495.</P> <P><B>Highlights</B></P> <P> <UL> <LI> This study was a prospective randomized phase II, multicentre study comparing EG with PG for MBC patients. </LI> <LI> The 6-month PFS rates for both arms were 72% for EG and 73% for PG (<I>P</I> = 0.457). </LI> <LI> EG chemotherapy had similar clinical benefits to PG chemotherapy in terms of progression-free survival but less neurotoxicity. </LI> </UL> </P>
연관 검색어 추천
이 검색어로 많이 본 자료
활용도 높은 자료
